Dr. Boisen on Scoring System for Optimal Debulking in Ovarian Cancer

Video

Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.

Michelle M. Boisen, MD, assistant professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the scoring system for optimal debulking in ovarian cancer.

A few trials were published that looked at developing a scoring system to predict how likely a patient would be successfully optimally debulked, says Boisen. The goal of all these surgies is to get patients to <1 cm of residual disease with, ideally, no visible residual disease. A scoring system was developed based on the location of patients’ disease and determined that if a patient has a score of <8 versus >8, then their chance of being optimally debulked is “X.”

At UPMC, something similar is done where a scope is put in and it's used to assess the disease on the diaphragm, the liver surface, and the stomach. Then patients are scored and triaged based on that information, concludes Boisen.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine